S. Wright

发表

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

D. Altman, P. Duncombe, S. Wright, 2012, Trials.

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.

M. Fallon, A. Lichtman, S. Rossetti, 2017, Journal of pain and symptom management.

Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies

M. Fallon, A. Lichtman, S. Rossetti, 2017, British journal of pain.

Results of a double-blind, randomized, placebo-controlled study of Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic uncontrolled pain

M. Fallon, A. Lichtman, S. Rossetti, 2017 .

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray

G. Guy, D. Wilbraham, S. Wright, 2012, European Journal of Clinical Pharmacology.

Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.

M. Selikowitz, A. Pendergast, S. Wright, 1990, Archives of disease in childhood.

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

P. McGuire, P. Morrison, W. Cubała, 2017, The American journal of psychiatry.

Pharmacokinetics and Disposition

G. Guy, D. Wilbraham, S. Wright, 2022 .

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

A. Hart, S. Bloom, J. Lindsay, 2018, Inflammatory bowel diseases.

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis

G. Giovannoni, G. Pryce, G. Guy, 2012, ISRN neurology.

Licensed Cannabis-Based Medicines: Benefits and Risks

G. Guy, S. Wright, 2014 .

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

S. Wright, H. Lauder, Adam Taylor, 2016, Therapeutics and clinical risk management.

A Multiple‐Dose, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray

E. Sellers, P. Duncombe, Chien-Feng Chen, 2013, Clinical pharmacology in drug development.

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

M. Huestis, S. Wright, W. Darwin, 2011, Clinical chemistry.

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

E. Dunayevich, O. Devinsky, E. Thiele, 2020, Acta neurologica Scandinavica.

Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome

I. Scheffer, O. Devinsky, I. Miller, 2017, The New England journal of medicine.

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

G. Guy, D. Wilbraham, S. Wright, 2013, SpringerPlus.

Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis

C. Bever, B. Weinstock-Guttman, D. Bourdette, 2014, Neurology.

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

O. Devinsky, I. Miller, R. Nabbout, 2018, Epilepsia.

Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration

M. Huestis, F. Liu, S. Wright, 2011, Clinical pharmacology and therapeutics.

Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence

S. Wright, 2007, Molecular Neurobiology.

Cannabidiol Does Not Convert to Δ9-Tetrahydrocannabinol in an In Vivo Animal Model

Nicholas A. Jones, S. Wright, C. Stott, 2017, Cannabis and cannabinoid research.

Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals’ Cannabidiol in the Anticonvulsant Screening Program (P2.038)

Nicholas A. Jones, S. Wright, C. Stott, 2016 .

Assessment of the Anticonvulsant Effects and Tolerability Profile of Cannabidiol: GW Pharmaceuticals’ Preclinical Program (P4.255)

Benjamin J. Whalley, C. Williams, Andrew J. Hill, 2015 .

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Orrin Devinsky, Stephen Wright, O. Devinsky, 2017, The New England journal of medicine.

The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

G. Guy, S. Wright, M. Ware, 2006, Rheumatology.

A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use

E. Sellers, G. Guy, M. Romach, 2011, Human psychopharmacology.

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

M. Fallon, R. Mcquade, R. Portenoy, 2012, The journal of pain : official journal of the American Pain Society.

PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis

S. Wright, T. Iqbal, C. Nwokolo, 2015 .

A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of Effect of Long-Term Sativex Treatment on Cognition and Mood of Patients with Spasticity Due to Multiple Sclerosis

J. Mareš, M. Vachová, R. Taláb, 2014 .

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

S. Wright, H. Lauder, Tilden Etges, 2016, Therapeutics and Clinical Risk Management.

P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users

E. Sellers, G. Guy, S. Wright, 2010, European Neuropsychopharmacology.

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray

G. Guy, D. Wilbraham, S. Wright, 2013, European journal of clinical pharmacology.

Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

L. Dubé, S. Dahlén, B. Dahlén, 1998, American journal of respiratory and critical care medicine.

A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM).

C. Twelves, S. Short, S. Wright, 2017 .